Maintenance treatment with talazoparib plus immunotherapy for bladder cancer
Part of Cancer clinical trials.
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent before any study tests
- Your cancer is urothelial cancer (bladder, ureter, renal pelvis, or urethra) and the main type is transitional cell
- Your cancer is advanced (stage IV) and you cannot be cured with surgery or radiation at the start of first-line chemo
- You finished platinum chemotherapy (cisplatin or carboplatin) for advanced disease (at least 4 cycles, up to 6) and your scans show stable disease or a partial/complete response
- You are starting the study within 8 weeks after the last chemo dose, and about 3 weeks after that dose
- Your body tests are strong enough for treatment (bone marrow, liver, and kidney function), and you can take pills by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a maintenance drug called avelumab can help keep metastatic bladder cancer from growing after patients have already responded to two prior treatments. It is for patients who had a specific sequence of therapies and whose cancer is stable after second-line chemotherapy.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.